

Isabelle Fajac

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3129047/publications.pdf>

Version: 2024-02-01

10
papers

427
citations

1162367

8
h-index

1281420

11
g-index

12
all docs

12
docs citations

12
times ranked

642
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2014, 2, 539-547. | 5.2 | 301 |
| 2 | Amikacin liposome inhalation suspension for chronic <i>Pseudomonas aeruginosa</i> infection in cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2020, 19, 284-291. | 0.3 | 34 |
| 3 | Long-term computed tomographic changes in cystic fibrosis patients treated with ivacaftor. <i>European Respiratory Journal</i> , 2016, 48, 249-252. | 3.1 | 30 |
| 4 | Insights into the variability of nasal potential difference, a biomarker of CFTR activity. <i>Journal of Cystic Fibrosis</i> , 2020, 19, 620-626. | 0.3 | 14 |
| 5 | Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic <i>P. aeruginosa</i> infection. <i>Journal of Cystic Fibrosis</i> , 2021, 20, 1010-1017. | 0.3 | 11 |
| 6 | Persistent Nasal Inflammation 5 Months after Acute Anosmia in Patients with COVID-19. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 1319-1322. | 2.5 | 10 |
| 7 | Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2021, 20, 1026-1034. | 0.3 | 9 |
| 8 | Real-World Long-Term Ivacaftor for Cystic Fibrosis in France: Clinical Effectiveness and Healthcare Resource Utilization. <i>Pulmonary Therapy</i> , 2021, 7, 455-468. | 1.1 | 8 |
| 9 | Riociguat for the treatment of Phe508del homozygous adults with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2021, 20, 1018-1025. | 0.3 | 5 |
| 10 | A new Clinical Trials Directive to boost academic trials?. <i>Lancet Respiratory Medicine</i> , 2013, 1, 99-101. | 5.2 | 3 |